Ad Astra Awards
Ad Astra Journal
Science library
White book
University rankings
Who's who
Publications
Theses and dissertations
Ad Astra association
 
Press releases
News
Events
Funding opportunities
 
Login
Registration
 
>> Românã
 
   
 

Banciu, M., Metselaar, J. M., Schiffelers, R. M., Storm, G. . Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice. . Journal of Steroid Biochemistry and Molecular Biology , 111(1-2), pp. 101-110 , 2008.

Abstract: This study evaluates whether the inhibitory effects of prednisolone phosphate (PLP) encapsulated in longcirculating
liposomes (LCL-PLP) on tumor growth and tumor angiogenesis described previously can be
generalized to other types of glucocorticoids (GC) encapsulated in LCL (LCL-GC). Four types of synthetic
GC, i.e. budesonide disodium phosphate (BUP), dexamethasone disodium phosphate (DXP), methylprednisolone
disodium phosphate (MPLP), and PLP, were selected based on the difference in their potency
to activate the human glucocorticoid receptor. The effects of all LCL-GC on the production of angiogenic/
inflammatory factors in vivo in the B16.F10 murine melanoma model as well as on the viability
and proliferation of tumor cells and endothelial cells in vitro were investigated.
Our results show that all four selected LCL-GC formulations inhibit tumor growth, albeit to different
degrees. The differences in antitumor activity of LCL-GC correlate with their efficacy to suppress
tumor angiogenesis and inflammation. The strongest antitumor effect is achieved by LCL-encapsulated
BUP (LCL-BUP), due to the highest potency of BUP versus the other three GC types. The in vitro results
presented herein suggest that LCL-BUP has strong cytotoxic effects on B16.F10 melanoma cells and the
anti-proliferative effects of all LCL-GC towards angiogenic endothelial cells play a role in their antitumor
activity.

Keywords: Glucocorticoids, Liposomes, Angiogenesis, Inflammation, Cancer

Posted by Manuela Banciu

Back

   
© Ad Astra 2001-2013